

ERS Research Seminar

***New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine***

09 – 10 May 2019; Paris, France

**Day 1 – Thursday, 09 May 2018**

08:30-08:45: Registration

08:45-09:00: Introduction (Jacques Cadranel and Thierry Berghmans)

**Session 1: From molecular alterations to cancer immunity in NSCLC**

**Chairs:** P. Pauwels and T. Berghmans

09:00-09:25: What are the main mechanisms of oncogenic addiction? (Joanna Chorostowska, PL)

09:25-09:50: Are KRAS mutations druggable? (Marina Garassino, IT)

09:50-10:15: How does the cancer immunity circle operate (or dysoperate)? (Joachim Aerts, NL)

10:15-10:40: *Panel discussion*

10:40-11:00: *Coffee break*

**Session 2: From molecular target to molecular resistance in NSCLC**

**Chairs:** J. Aerts and D. Planchard

11:00-11:25: Molecular diagnosis for oncogenic addictions (Patrick Pauwels, BL)

11:25-11:50: When and how to identify resistance mechanisms to targeted therapies (Nicolas Girard, FR)

11:50-12:15: Predictive biomarker of immune checkpoint inhibitors efficacy (Luis Paz-Ares, SP)

12:15-12:40: *Panel discussion*

12:40-14h00: *Lunch*

**14:00-15:30 Session 3: From molecular addiction to therapeutic strategy in NSCLC**

**Chairs:** M. Garassino, J. Chorostowska

14:00-14:25: Therapeutic strategy for EGFR driven NSCLC (Jacques Cadranel, FR)

14:25-14:50: Therapeutic strategy for ALK/ROS driven NSCLC (Jan Van Meerbeeck, BL)

14:50-15:15: Therapeutic strategy for other oncogenic drivers (David Planchard, FR)

15:15-15:40: *Panel discussion*

15:40-16:00: *Coffee break*

**16:00-17:45: Session 4 – Breakout – Difficult situations in the era of targeted therapies**

Group 1. How to manage brain metastasis – *chairs: L. Hendriks and T. Berghmans*

Group 2. How to manage diagnostic resistance – *chairs: J. Chorostowska and N. Girard*

Group 3. How to manage specific toxicities of targeted therapies – *chairs: A.M. Dingemans and D. Planchard*

Group 4. Which sequence for TKI, ICI and conventional chemotherapy – *chairs: L. Paz Ares and J. Cadranel*

17:45-18:00: Urgent questions

From 19h00: *Dinner*

**Day 2 – Friday, 10 May 2018**

**Session 5: From PD1/PD-L1 monotherapy in selected patients to PD1/PD-L1 combo for all NSCLC**

**Chairs:** J. Van Meerbeeck and J. Cadranel

09:00-09:20: From anti-PD1/L1 inhibitors to new immunotherapies (Thierry Berghmans, BL)

09:20-09:40: Which immunotherapy for which patients? (Lizza Hendriks, NL)

09:40-10:00: Combination therapy in the era of immunotherapy (Anne-Marie Dingemans, NL)

10:00-10:15: *Panel discussion*

10:15-10:45: *Coffee break*

**Session 6: General podium discussion on research priorities**

**Chairs:** J. Cadranel and T. Berghmans

10:45-11:45: Summary of working groups: 15' per group

11:45-12:30: Whole faculty and all participants

12:30-14:00: *Lunch and departure*